Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Operators should consult qualified counsel for guidance on specific products and jurisdictions. While we strive for accuracy, the dynamic nature of the cannabis industry means information may change, and we cannot guarantee its timeliness or completeness. Users are responsible for their decisions based on our content, and we disclaim liability for actions taken as a result.
Table of Contents
The American Trade Association for Cannabis and Hemp (ATACH) has released the 2026 Hemp Intoxicants Report, one of the first comprehensive looks at how P.L. 119‑37 and state‑level actions will reshape the hemp, CBD, and THC beverage landscape under a new federal hemp definition taking effect November 12, 2026. CannabisTech is publishing this explainer to help brands, retailers, investors, and other hemp‑derived product stakeholders use the report as a roadmap and briefing book for the next 18 months, understand the shifting rules, and begin planning for what comes next.
Why this report matters now
ATACH’s 2026 Hemp Intoxicants Report arrives just months after Congress enacted P.L. 119‑37 in November 2025, reshaping federal hemp law for the first time since the 2018 Farm Bill. It pulls the new federal definition, state responses, and early market shifts into a single resource at a time when rules are still being written in real time.
The policy environment is moving quickly: Congress has acted, the marijuana rescheduling process continues, CMS has launched a hemp‑related pilot, and states are advancing bills and enforcement actions targeting intoxicating hemp products. ATACH’s report gives industry, regulators, and consumers a shared reference point for understanding what is changing and when.
What Congress changed: Closing the “hemp loophole”
At the center of the report is P.L. 119‑37, which rewrites the federal definition of hemp and targets the unregulated synthetic THC market that grew after 2018.
Under the new law:
- The former delta‑9‑only test is replaced by a total THC framework, so regulators consider all intoxicating THC, not just delta‑9.
- Finished products must meet a 0.4 mg total THC per container cap to qualify as hemp, a threshold that will disqualify many higher‑dose intoxicating edibles and beverages.
- Synthetic and chemically converted cannabinoids (including many products derived from CBD or other precursors, such as common forms of delta‑8 and related compounds) are excluded from the definition of hemp and hemp cannabinoid products.
In practice, a large portion of the “intoxicating hemp” category—particularly products marketed as legal intoxicants outside state‑licensed cannabis systems—will lose hemp status once the new definition takes effect on November 12, 2026.
What’s in the ATACH 2026 Hemp Intoxicants Report
ATACH’s document functions as both a legal overview and a map of how policy and markets are shifting. It focuses on four main areas:
Federal law changes
The report traces the path from the 2018 Farm Bill to P.L. 119‑37, explaining why Congress moved to tighten the hemp definition and how total THC and synthetic cannabinoid exclusions became central. It situates the new law alongside rescheduling discussions and emerging federal health‑care experiments with hemp‑derived products.
State landscape
ATACH groups state approaches into six regulatory archetypes, documents enforcement activity in 24 states, and tracks more than 45 bills introduced in the 2025–2026 sessions. This helps operators assess whether their markets are moving toward bans, tighter caps, integration with cannabis programs, or more permissive models.
CBD’s status
CBD has a clearer federal legal foundation because intoxicating hemp products are carved out and total THC is defined, but a complete consumer product pathway through FDA is still missing. That leaves open questions around dosing, claims, and product formats.
THC beverages
The report treats THC beverages separately from other intoxicating hemp products, highlighting several state models where regulators are creating distinct rules for drinks.
Overall, the report offers a snapshot of the current regulatory map and some directional indicators for the post‑2026 environment.
The state landscape: Six regulatory archetypes
ATACH’s six archetypes are intended to simplify a complex patchwork of state rules into recognizable patterns.
Examples include:
- States moving toward broad bans or near‑bans on intoxicating hemp outside licensed cannabis channels.
- States allowing intoxicating hemp with strict potency caps, age‑gating, and labeling requirements, often moving toward the federal total THC standard.
- States that integrate intoxicating hemp into adult‑use or medical cannabis programs, applying similar licensing and tracking.
- States testing pilot or hybrid approaches, particularly for beverages.
Alongside these archetypes, ATACH highlights concrete enforcement actions—such as product seizures and warning letters—in at least 24 states, as well as pending legislation that could shift jurisdictions between archetypes before the federal effective date.
CBD’s new footing—and remaining gaps
One of the more significant implications of P.L. 119‑37, as reflected in the report, is that CBD now sits on firmer federal ground because Congress has differentiated between compliant hemp and intoxicating hemp products.
ATACH also notes important limitations:
- A comprehensive FDA regulatory pathway for CBD consumer products has not yet been established.
- While the new law clarifies basic CBD legality, brands still face uncertainty around labeling, marketing, and cross‑state standards.
- CMS and Medicare pilots involving hemp‑derived CBD suggest that more formal health‑care channels for certain products could emerge before a broad FDA consumer framework is in place.
For CBD‑focused companies, the report suggests that the regulatory baseline is stabilizing, but the longer‑term framework remains a work in progress.
THC beverages: A distinct regulatory conversation
ATACH devotes a separate section to THC beverages, reflecting the fact that drinks are increasingly treated as a distinct category.
Key themes include:
- States experimenting with alcohol‑analog models, such as beverage‑specific potency caps and distinctions between on‑premise and off‑premise sales.
- Jurisdictions integrating THC beverages into cannabis regulatory systems rather than treating them as hemp products, particularly in adult‑use markets.
- Tension between the federal 0.4 mg per‑container hemp cap and state‑level allowances for higher‑dose beverages within licensed cannabis channels.
The report frames THC beverages as an early test of how regulators balance consumer demand, analogies to alcohol, and public health concerns.
2026 as a transition year for finance and supply chains
ATACH describes 2026 as a transition year, in which financial institutions, insurers, and supply chains are adjusting their risk posture ahead of the November 12, 2026 deadline.
According to the report and related analysis:
- Banks and payment processors are tightening onboarding and monitoring to reduce exposure to products unlikely to qualify as hemp under the new total THC and synthetic cannabinoid rules. For a deeper look at how specialized fintech providers are building banking and payments infrastructure around evolving cannabis and hemp regulations, see Safe Harbor’s next‑chapter overview on fintech and payments resilience.
- Insurers are revisiting coverage for intoxicating hemp, with closer attention to product liability, labeling, and adherence to evolving state rules.
- Distributors and retailers are starting product audits, renegotiating terms, and adjusting assortments toward products expected to remain compliant after 2026.
ATACH’s framing suggests that risk management work is already underway and is not being deferred to late 2026.
What you should do now
Translating the report into practical steps depends on your role, but several themes are consistent across the supply chain.
Brands and manufacturers
- Audit product lines
Identify SKUs that exceed 0.4 mg total THC per container or rely on synthetic or chemically converted cannabinoids, and flag them for further review. - Segment by likely post‑2026 status
Group products into those likely to remain compliant, those that may be reformulated, and those that appear unlikely to meet the new hemp definition. - Plan reformulation and relabeling timelines
Allow time for formulation changes, testing, packaging updates, and supply‑chain adjustments, recognizing that these processes typically take multiple quarters.
Retailers and e‑commerce
- Assess inventory risk
Review shelves and online assortments for products that are likely to lose hemp status and quantify exposure by category and vendor. - Address contracts and returns early
Engage suppliers on phase‑out plans and potential returns or markdown structures for at‑risk inventory rather than waiting until late 2026. - Align with your state’s regulatory trajectory
Use the archetypes described in the report to understand how your key states are likely to treat intoxicating hemp and align age‑gating, licensing, and compliance tools accordingly.
Investors and lenders
- Re‑evaluate portfolio exposure
Identify companies heavily dependent on products unlikely to qualify as hemp after 2026 and revisit risk assessments, terms, and valuation assumptions. - Focus on “regulation‑ready” segments
Consider opportunities in compliant CBD, low‑dose beverages that fit emerging models, and infrastructure solutions that help operators manage new requirements. - Monitor state developments systematically
Use ATACH’s frameworks and bill tracking as inputs for scenario planning rather than assuming a uniform national environment.
What to watch before November 12, 2026
ATACH presents the 2026 Hemp Intoxicants Report as a snapshot, and several variables could shift the picture before the new federal definition takes effect.
Key areas to monitor include:
- Follow‑on federal actions related to P.L. 119‑37, including potential clarifications, technical changes, or efforts to adjust timelines.
- FDA guidance on CBD and other cannabinoids, which would further define product standards, claims, and permissible formats.
- CMS and payer behavior, particularly the results of hemp‑related pilots in Medicare Advantage and related programs.
- State legislation and rulemaking, as jurisdictions adjust their laws and regulations to align with or diverge from the new federal standard.
The ATACH 2026 Hemp Intoxicants Report makes clear that the era of building product strategies around ambiguity in the hemp definition is ending, and that positioning for the new regime requires proactive planning well before late 2026.
